How will physicians respond to the next influenza pandemic?

Clinical Infectious Diseases

Volumn 58, Issue 2, 2014, Pages 233-237

  Fedson, David S ^a  

^a Sergy Haut ^*  (France)

Author keywords

Immunomodulatory agents; Pandemic influenza; Public health; Statins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIVIRUS AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE;

CHINA; CLINICAL TRIAL (TOPIC); CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG SAFETY; EXTRACORPOREAL OXYGENATION; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HOSPITAL DISCHARGE; HUMAN; IMMUNE DYSREGULATION; IMMUNE RESPONSE; INFLUENZA; INFLUENZA A (H5N1); INFLUENZA VIRUS A H7N9; MORTALITY; PANDEMIC; PATIENT CARE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; REVERSE GENETICS; REVIEW; VACCINATION;

IMMUNOMODULATORY AGENTS; PANDEMIC INFLUENZA; PUBLIC HEALTH; STATINS;

ANIMALS; CHINA; CIVIL DEFENSE; HEALTH SERVICES ADMINISTRATION; HUMANS; IMMUNOLOGIC FACTORS; INFLUENZA, HUMAN; PANDEMICS;

EID: 84891810978     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit695     Document Type: Review

References (40)

1. Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 368:2277-85
2. Ke Y, Wang Y, Liu S, et al. High severity and fatality of human infections with avian influenza A(H7N9) infection in China. Clin Infect Dis 2013; 57:1506-7
3. Yu L, Wang Z, Chen Y, et al. Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A(H7N9) virus. Clin Infect Dis 2013; 57:1449-57
4. Webster RG, Campbell CH. Studies on the origin of pandemic influenza. IV. Selection and transmission of "new" influenza viruses in vivo. Virology 1974; 62:404-13
5. Murray CJL, Lopez AD, Chin B, Feehan D, Hill KH. Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: A quantitative analysis. Lancet 2006; 368:2211-8
6. Russell CA, Fonville JM, Brown AEX, et al. The potential for respiratory droplet-Transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science 2012; 336:1541-7
7. Morens DM, Taubenberger JK, Fauci AS. H7N9 avian influenza A virus and the perpetual challenge of potential human pandemicity. MBio 2013; 4:e00445-13
8. Uyeki TM, Cox NJ. Global concerns regarding novel influenza A (H7N9) virus infections. N Engl J Med 2013; 368:1862-4
9. Osterholm MF, Ballering KS, Kelley NS. Major challenges in providing an effective and timely pandemic vaccine for influenza A(H7N9). JAMA 2013; 309:2557-8
10. Pavia AT. Influenza A(H7N9): From anxiety to preparedness. Ann Intern Med 2013; 159:219-20
11. Subbarao K, Matsuoka Y. The prospects and challenges of universal vaccines for influenza. Trends Microbiol 2013; 21:350-8
12. Fedson DS. New technologies for meeting the global demand for pandemic influenza vaccines. Biologicals 2008; 36:346-9
13. Palache A. Seasonal influenza vaccine provision in 157 countries (2004-2009) and the potential influence of national health policies. Vaccine 2011; 29:9459-66
14. Nguyen-van-Tam JS, Sellwood C. Preparing for a potential A(H7N9) pandemic: Lessons from the deployment of A(H1N1) pandemic vaccines. Expert Rev Vaccines 2013; 12:825-8
15. Borse RH, Shrestha SS, Fiore AE, et al. Effect of vaccine program against pandemic influenza A(H1N1) virus, United States, 2009-2010. Emerg Infect Dis 2013; 19:439-48
16. Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res 2013; 99:417-35
17. Starr I. Influenza in 1918: Recollections of the epidemic in Philadelphia. Ann Intern Med 2006; 145:138-40
18. Korth MJ, Tchitchek N, Benecke AG, Katze MG. Systems approaches to influenza-virus host interactions and the pathogenesis of highly virulent and pandemic viruses. Sem Immunol 2012. doi:10.1016/j.smim. 2012.11.001. In press
19. Fedson DS. Pandemic influenza: A potential role for statins in treatment and prophylaxis. Clin Infect Dis 2006; 43:199-205
20. Singla S, Jacobson Jr. Statins as a novel therapeutic strategy in acute lung injury. Pulm Circ 2013; 2:397-406
21. Di Raimondo D, Tuttolomondo A, Butta D, Miceli S, Licata G, Pinto A. Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation. Curr Pharmacol Des 2012; 18:4385-413
22. Steinberg BE, Goldenberg NM, Lee WL. Do viral infections mimic bacterial sepsis? The role of microvascular permeability: A review of mechanisms and methods. Antiviral Res 2012; 93:2-15
23. Carre JE, Orban JC, Re L, et al. Survival in critical illness is associated with early activation of mitochondrial biogenesis. Am J Respir Crit Care Med 2010; 182:745-51
24. Liu TF, Brown CM, El Gazzar M, et al. Fueling the flame: Bioenergy couples metabolism and inflammation. J Leukoc Biol 2012; 92: 499-507
25. Rathmell JC. Metabolism and autophagy in the immune system: Immunomodulation comes of age. Immunol Rev 2012; 249:5-13
26. Verbist KC, Wang R, Green DR. T cell metabolism and the immune response. Sem Immunol 2012; 24:399-404
27. Medzhitov R, Schneider DS, Soares MP. Disease tolerance as a defense strategy. Science 2012; 335:936-41
28. Suber F, Kobzik L. Modeling childhood resistance to influenza mortality: Increased survival in pre-pubertal and delayed puberty mice. Am J Respir Crit Care Med 2013; 187:A1704
29. Burger O, Baudisch A, Vaupel JW. Human mortality improvement in evolutionary context. Proc Natl Acad Sci U S A 2012; 109:18210-4
30. Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory- confirmed influenza virus infections: A multistate study. J Infect Dis 2012; 205:13-9
31. Mortensen EM, Nakashima B, Cornell J, et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis 2012; 55:1466-73
32. Patel JM, Snaith C, Thickett DR, et al. Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS) Trial. Crit Care 2012; 16: R231
33. Leung A, Schaefer EW, Tempelhof MW, Stone NJ. Emphasizing statin safety in the hospitalized patient: A review. Am J Med 2012; 125: 845-53
34. Doshi SM, Kulkarni PA, Liao JM, Rueda A, Musher DM. The impact of statin and macrolide use on early survival in patients with pneumococcal pneumonia. Am J Med Sci 2013; 345:173-7
35. Lurie N, Maniolo T, Patterson AP, Collins F, Frieden T. Research as a part of public health emergency response. N Engl J Med 2013; 368:1251-5
36. Fedson DS. Meeting the challenge of influenza pandemic preparedness in developing countries. Emerg Infect Dis 2009; 15:365-71
37. Infectious Diseases Society of America. Pandemic and seasonal influenza. Principles for United States action. Available at: Http://www. idsociety.org/Biothreat-Policy/. Accessed 30 September 2013
38. World Health Organization. Pandemic influenza preparedness framework for the sharing of influenza viruses and access to vaccine and other benefits. Geneva, Switzerland: WHO. 16 April 2011. Available at: Http://www.who.int/csr/ disease/influenza/pip-framework-16-April-2011. pdf. Accessed 30 September 2013
39. World Health Organization. Pandemic influenza preparedness: Sharing of influenza viruses and access to vaccines and other benefits. Report of the meeting of the Pandemic Influenza Preparedness Framework Advisory Group. Sixty-sixth World Health Assembly A66/17 Add.1, Provisional agenda item 15.2. 14 May 2013. Available at: Http://apps.who.int/gb/ebwha/pdf-files/WHA66/A66- 17Add1-en.pdf. Accessed 30 September 2013
40. Orwell G. In front of your nose. Tribune, 22 March 1946. In: Orwell S, Angus I, eds. The collected essays, journalism and letters of George Orwell. Vol 4. Harmondsworth, UK: Penguin Books, Ltd, 1970: 154